139487-69-7

Basic information

• Product Name: 6-bromopicolinic acid chloride
• Synonyms: 6-bromopicolinic acid chloride;2-Bromopyridine-6-carbonyl chloride
• CAS NO: 139487-69-7
• Molecular Formula: C₆H₃BrClNO
• Molecular Weight: 220
• Mol File: 139487-69-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 6-bromopicolinic acid chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 6-bromopicolinic acid chloride(139487-69-7)
• EPA Substance Registry System: 6-bromopicolinic acid chloride(139487-69-7)

Safety Data

• Hazardous Substances Data: 139487-69-7(Hazardous Substances Data)

Upstream product

• 6937-16-2 ethyl γ-aminobutyrate hydrochloride 
• 21190-87-4 6-bromo-pyridine-2-carboxylic acid 
• 5315-25-3 2-bromo-6-methylpyridine 

Downstream Products

• 1373270-41-7 6-(4-{1-[(2-chloro-4-fluorophenyl)methyl]piperidin-4-yl}-5,5-dideutero-1,4-diazepan-1-yl)-N-(pyridin-4-yl)pyridine-2-carboxamide 
• 341556-25-0 1-(6-bromopyridin-2-yl)propan-1-one 
• 1375217-85-8 3-(4'-methoxy-6'-methyl-[2,2']bipyridinyl-6-yl)prop-2-yn-1-ol 
• 1375217-79-0 4-benzyloxy-6'-bromo-6-methyl-[2,2]bipyridinyl 
• 1375217-78-9 (E)-1-(6-methyl-pyridin-2-yl)-ethanone-O-[3-(4'-benzyloxy-6'-methyl-[2,2']bipyridinyl-6-yl)-prop-2-ynyl]-oxime 
• 819083-98-2 6-bromo-2-[(S)-4,5-dihydro-4-isopropyl-1,3-oxazol-2-yl]pyridine 
• 909292-48-4 2-amino-1-(6-bromopyridin-2-yl)ethanone hydrochloride 
• 1173834-41-7 C₁₉H₂₀BrClN₄O 
• 337535-94-1 6-bromo-N-methylpicolinamide 
• 25194-52-9 6-bromo-pyridine-2-carboxylic acid amide 
• 20845-22-1 1-methyl-6-oxo-1,6-dihydropyridine-2-carboxylic acid methyl ester 

Relevant articles and documents

Discovery of AZD8154, a Dual PI3Kγδ Inhibitor for the Treatment of Asthma

Starting from our previously described PI3Kγ inhibitors, we describe the exploration of structure-activity relationships that led to the discovery of highly potent dual PI3Kγδ inhibitors. We explored changes in two positions of the molecules, including macrocyclization, but ultimately identified a simpler series with the desired potency profile that had suitable physicochemical properties for inhalation. We were able to demonstrate efficacy in a rat ovalbumin challenge model of allergic asthma and in cells derived from asthmatic patients. The optimized compound, AZD8154, has a long duration of action in the lung and low systemic exposure coupled with high selectivity against off-targets.

Enhancing performance for blue TADF emitters by introducing intramolecular CH?N hydrogen bonding between donor and acceptor

Three novel thermally activated delayed fluorescence (TADF) emitters, named MCZ-B-DTM, MCZ-P2-DTM and MCZ-P3-DTM are designed and synthesized for fabricating blue emission devices. The position of nitrogen atom in pyridine ring is varied relative to the donor unit and the presence of CH?N hydrogen bonding in MCZ-P3-DTM is confirmed by theoretic simulation and 1H NMR analysis. Due to the introduction of CH?N hydrogen bonding between donor and acceptor, the dihedral angles, photophysical properties, together with thermal stabilities, of the targeted compounds are regulated ingeniously. As a consequence, MCZ-P3-DTM displays an increase of the molar extinction coefficient obviously and offers a higher PLQY of 60.1%. The TADF device adopting MCZ-P3-DTM as emitter shows a maximum external quantum efficiency (EQE) of 12.1%, which is superior to those of MCZ-B-DTM and MCZ-P2-DTM, demonstrating the introducing of intramolecular hydrogen bonding interactions between donor and acceptor is an efficient strategy for future structural design of TADF emitters.

Structure-based design and profiling of novel 17β-HSD14 inhibitors

The human enzyme 17β-hydroxysteroid dehydrogenase 14 (17β-HSD14) oxidizes the hydroxyl group at position 17 of estradiol and 5-androstenediol using NAD+ as cofactor. However, the physiological role of the enzyme remains unclear. We recently des

Phenylpyridine compound and preparation and application thereof

The invention discloses a phenylpyridine compound and preparation and application thereof. The compound is used as a tumor multidrug resistance reversal agent and a chemotherapeutic drug sensitizer. Pharmacological experiment results show that the compound provided by the invention has excellent tumor multidrug resistance reversal activity and sensitization chemotherapy drug activity, and can be clinically used as a malignant tumor multidrug resistance reversal agent and a chemotherapy drug sensitizer.

HETEROCYCLIC COMPOUNDS AND USES THEREOF

Heterocyclic compounds as Wee1 inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.

Pyridine-amide-oxazoline ligand, synthesizing method, metal complex and application thereof

The invention discloses a pyridine-amide-oxazoline ligand. The ligand is a compound as shown in a formula (I) or antimer or despinner of the compound as shown in the formula (I), wherein R1 and R2 arerespectively one of hydrocarbyl, benzyl, phenyl or subs

QUINOLINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS

Disclosed are imidazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure (I) and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein R1, X, Y1, Y2, Y3 and Z are as described herein. In certain embodiments, a compound disclosed herein inhibits a cellular TAM receptor, and can be used to treat disease mediated by or involving the TAM receptor family.

ANTIBACTERIAL THERAPEUTICS AND PROPHYLACTICS

The present disclosure relates generally to novel molecules, compositions, and formulations for treatment of bacterial infections in general and more specifically to bacterial infections with antibiotic resistant pathogens.

Discovery of novel Ponatinib analogues for reducing KDR activity as potent FGFRs inhibitors

FGF receptors (FGFRs) are tyrosine kinases that are overexpressed in diverse tumors by genetic alterations such as gene amplifications, somatic mutations and translocations. Owing to this characteristic, FGFRs are attractive targets for cancer treatment. It has been demonstrated that most multi-targeted, ATP competitive tyrosine kinase inhibitors are active against FGFRs as well as other kinases. The design of new and more selective inhibitors of FGFRs, which might be reduced off-target and side effects, is a difficult yet significant challenge. The results of the current investigation, show that novel Ponatinib analogues are highly active as FGFR inhibitors and that they possess reduced kinase insert domain receptor (KDR) activities. Observations made in a structure and activity relationship (SAR) investigation led to the development of a promising, orally available lead compound 4, which displays a 50–100 fold in vitro selectivity for inhibition of FGFR1-3 over KDR. In addition, biological evaluation of compound 4 showed that it displays significant antitumor activities in FGFR1-amplificated H1581 and FGFR2-amplificated SNU-16 xenograft models.

PYRIMIDINE AND TRIAZINE DERIVATIVES AND THEIR USE AS AXL INHIBITORS

Compounds of the general formula(I): (I) processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.